Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Short-term Investments (2020 - 2025)

Mirum Pharmaceuticals has reported Short-term Investments over the past 6 years, most recently at $86.6 million for Q4 2025.

  • Quarterly results put Short-term Investments at $86.6 million for Q4 2025, up 49.87% from a year ago — trailing twelve months through Dec 2025 was $86.6 million (up 49.87% YoY), and the annual figure for FY2025 was $86.6 million, up 49.87%.
  • Short-term Investments for Q4 2025 was $86.6 million at Mirum Pharmaceuticals, down from $93.5 million in the prior quarter.
  • Over the last five years, Short-term Investments for MIRM hit a ceiling of $149.6 million in Q3 2022 and a floor of $3.0 million in Q3 2023.
  • Median Short-term Investments over the past 5 years was $84.6 million (2023), compared with a mean of $86.4 million.
  • Biggest five-year swings in Short-term Investments: tumbled 98.01% in 2023 and later soared 1969.2% in 2024.
  • Mirum Pharmaceuticals' Short-term Investments stood at $125.2 million in 2021, then decreased by 1.19% to $123.7 million in 2022, then crashed by 97.6% to $3.0 million in 2023, then soared by 1845.88% to $57.8 million in 2024, then surged by 49.87% to $86.6 million in 2025.
  • The last three reported values for Short-term Investments were $86.6 million (Q4 2025), $93.5 million (Q3 2025), and $76.4 million (Q2 2025) per Business Quant data.